PTC Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Gain
PTC Therapeutics, Inc. (PTCT) reported Debt Securities, Available-for-sale, Unrealized Gain of $2.10 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-10-28.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain · last filed 2021-10-28
- PTC Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2021-09-30 was -$2.20M, a 257.14% decline year-over-year.
- PTC Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2021-06-30 was -$3.60M, a 271.43% decline year-over-year.
- PTC Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2021-03-31 was $7.90M, a 182.14% increase year-over-year.
- PTC Therapeutics, Inc. debt securities, available-for-sale, unrealized gain for the quarter ending 2020-09-30 was $1.40M.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain 3 month | Debt Securities, Available-for-sale, Unrealized Gain 6 month | Debt Securities, Available-for-sale, Unrealized Gain 9 month |
|---|---|---|---|
| 2021-09-30 | -$2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | -$5.80M derived: sum of 2 quarters · filed 2021-10-28 | $2.10M 10-Q · filed 2021-10-28 |
| 2021-06-30 | -$3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $4.30M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $7.90M 10-Q · filed 2021-05-04 | ||
| 2020-09-30 | $1.40M 10-Q · filed 2021-10-28 | $3.50M derived: sum of 2 quarters · filed 2021-10-28 | $600.00K 10-Q · filed 2020-10-29 |
| 2020-06-30 | $2.10M 10-Q · filed 2021-07-29 | $4.90M derived: sum of 2 quarters · filed 2021-07-29 | |
| 2020-03-31 | $2.80M 10-Q · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |